1. Which statement most precisely describes the location and transport characteristics of the sodium-glucose cotransporter 2 (SGLT-2)?
A) SGLT-2 is located in the late proximal tubule (S3 segment) and is a high-affinity, low-capacity transporter that reabsorbs about 10% of filtered glucose
B) SGLT-2 is located in the early proximal tubule (S1 and S2 segments) and is a low-affinity, high-capacity transporter that reabsorbs approximately 90% of filtered glucose
C) SGLT-2 is located on the basolateral membrane of the proximal tubule and exports reabsorbed glucose into the interstitium
D) SGLT-2 is located in the thick ascending limb of the loop of Henle and couples glucose reabsorption to potassium transport
E) SGLT-2 is located in the intestinal brush border and mediates dietary glucose absorption rather than renal reabsorption
ANSWER: B
Rationale:
SGLT-2 is expressed predominantly in the early proximal tubule (S1 and S2 segments) and is a low-affinity but high-capacity transporter responsible for approximately 90% of renal glucose reabsorption. This makes it the principal pharmacologic target for glycosuric glucose lowering.
Option A: Option A is incorrect because the late proximal tubule (S3 segment), high-affinity, low-capacity, ~10% salvage description applies to SGLT-1, not SGLT-2.
Option C: Option C is incorrect because basolateral glucose export into the interstitium is performed by the facilitated transporter GLUT2, not by the luminal SGLT-2.
Option D: Option D is incorrect because SGLT-2 is not located in the thick ascending limb and does not couple glucose to potassium transport; it cotransports glucose with sodium in the proximal tubule.
Option E: Option E is incorrect because intestinal brush-border glucose absorption is mediated by SGLT-1, not by SGLT-2, which is a renal transporter.
2. After glucose is taken up across the luminal membrane of the proximal tubule cell by SGLT transporters, by which mechanism does it exit the cell into the interstitium?
A) Active extrusion by a luminal sodium-glucose cotransporter that pumps glucose against its gradient back into the blood
B) Primary active transport directly powered by ATP hydrolysis at the basolateral membrane
C) Co-transport with chloride across the basolateral membrane via a glucose-chloride symporter
D) Facilitated diffusion across the basolateral membrane through the glucose transporter 2 (GLUT2)
E) Endocytic vesicular transport that shuttles glucose across the cell without a membrane carrier
ANSWER: D
Rationale:
Glucose that has been concentrated inside the proximal tubule cell by luminal SGLT cotransport exits across the basolateral membrane into the interstitium by facilitated diffusion through GLUT2, moving down its concentration gradient.
Option A: Option A is incorrect because SGLT transporters are luminal uptake carriers, not basolateral exit carriers, and glucose exit is down-gradient facilitated diffusion rather than active extrusion.
Option B: Option B is incorrect because basolateral glucose exit is not directly ATP-powered; the energy for the overall process comes indirectly from the sodium gradient maintained by the basolateral sodium-potassium ATPase, while glucose itself leaves by facilitated diffusion.
Option C: Option C is incorrect because basolateral glucose exit occurs via GLUT2 facilitated diffusion, not via a glucose-chloride symporter.
Option E: Option E is incorrect because glucose crosses the basolateral membrane through the GLUT2 carrier, not by endocytic vesicular shuttling.
3. What is the approximate magnitude of weight reduction attributable to SGLT-2 inhibitor therapy, and what is its primary basis?
A) Approximately 2 to 3 kg over 24 to 52 weeks, driven primarily by the caloric loss of urinary glucose excretion (roughly 240 to 360 kilocalories per day)
B) Approximately 15 to 20 kg over 12 weeks, driven primarily by central appetite suppression
C) No meaningful weight change, because the calories lost in the urine are fully compensated by reduced energy expenditure
D) Approximately 2 to 3 kg over 24 to 52 weeks, driven primarily by direct lipolysis in adipose tissue independent of urinary glucose loss
E) Weight gain of approximately 2 to 3 kg, driven by fluid retention from sodium reabsorption
ANSWER: A
Rationale:
SGLT-2 inhibitors produce glycosuria of roughly 60 to 90 grams of glucose per day, corresponding to a caloric loss of approximately 240 to 360 kilocalories per day. This urinary caloric loss is the primary driver of the modest weight reduction of about 2 to 3 kg seen over 24 to 52 weeks.
Option B: Option B is incorrect because the weight loss is modest (2 to 3 kg), not 15 to 20 kg, and the mechanism is urinary caloric loss rather than central appetite suppression (which characterizes GLP-1 receptor agonists).
Option C: Option C is incorrect because a clinically meaningful, if modest, weight reduction does occur and is not fully offset by compensatory mechanisms.
Option D: Option D is incorrect because, although the magnitude is correct, the primary basis is urinary glucose caloric loss, not direct adipose lipolysis.
Option E: Option E is incorrect because SGLT-2 inhibitors cause natriuresis and volume reduction rather than sodium-driven fluid retention, and the net effect is weight loss, not weight gain.
4. SGLT-2 inhibitors produce a modest reduction in blood pressure. Which statement best characterizes the magnitude and mechanism of this effect?
A) A large reduction of approximately 20 to 30 mmHg systolic, mediated by direct arteriolar vasodilation
B) No change in blood pressure, because the natriuretic effect is fully offset by compensatory renin release
C) A modest reduction of approximately 3 to 5 mmHg systolic and 1 to 2 mmHg diastolic, mediated by osmotic diuresis and natriuresis that reduce extracellular fluid volume
D) A modest reduction of approximately 3 to 5 mmHg systolic, mediated primarily by central sympatholytic action in the brainstem
E) An increase of approximately 5 mmHg systolic, mediated by sodium retention and volume expansion
ANSWER: C
Rationale:
The osmotic diuresis and natriuresis produced by SGLT-2 inhibition reduce extracellular fluid volume by roughly 5 to 7%, producing a modest blood pressure reduction of approximately 3 to 5 mmHg systolic and 1 to 2 mmHg diastolic.
Option A: Option A is incorrect because the reduction is modest (a few mmHg), not 20 to 30 mmHg, and the mechanism is volume-mediated rather than direct arteriolar vasodilation.
Option B: Option B is incorrect because a measurable modest blood pressure reduction does occur and is not fully offset by compensatory renin release.
Option D: Option D is incorrect because, although the magnitude is approximately correct, the mechanism is osmotic diuresis and natriuresis with volume contraction, not central sympatholytic action.
Option E: Option E is incorrect because SGLT-2 inhibitors cause natriuresis and volume reduction, lowering rather than raising blood pressure.
5. Which pairing of SGLT-2 inhibitor selectivity characteristics is correct?
A) Empagliflozin has the greatest intestinal SGLT-1 activity, while canagliflozin is the most SGLT-2 selective agent
B) Dapagliflozin has substantial SGLT-1 activity at standard doses, while empagliflozin and canagliflozin are equally SGLT-2 selective
C) All four agents share identical selectivity, so SGLT-1 cross-activity is not a distinguishing feature
D) Ertugliflozin is the least selective agent and derives most of its effect from SGLT-1 blockade
E) Empagliflozin is the most SGLT-2 selective agent with negligible SGLT-1 activity, while canagliflozin has partial SGLT-1 inhibitory activity that becomes more pronounced at the 300 mg dose
ANSWER: E
Rationale:
Empagliflozin is the most SGLT-2 selective agent in the class with negligible SGLT-1 activity, and dapagliflozin is also highly selective. Canagliflozin has lower selectivity, with partial SGLT-1 inhibitory activity that is modest at 100 mg and more pronounced at 300 mg, transiently reducing post-meal intestinal glucose absorption.
Option A: Option A is incorrect because it reverses the relationship: canagliflozin (not empagliflozin) is the agent with SGLT-1 cross-activity, and empagliflozin is the most selective.
Option B: Option B is incorrect because dapagliflozin is highly SGLT-2 selective with minimal SGLT-1 activity, and empagliflozin and canagliflozin do not share equal selectivity.
Option C: Option C is incorrect because selectivity differs meaningfully across agents, with canagliflozin being the notable lower-selectivity agent.
Option D: Option D is incorrect because ertugliflozin does not derive most of its effect from SGLT-1 blockade; the class mechanism is renal SGLT-2 inhibition, and canagliflozin is the agent associated with SGLT-1 cross-activity.
6. What is the principal route of metabolism of the SGLT-2 inhibitor class?
A) Extensive first-pass oxidation by cytochrome P450 3A4 (CYP3A4), making the class highly susceptible to CYP3A4-mediated drug interactions
B) Hydrolysis by plasma esterases to inactive metabolites within minutes of absorption
C) Hepatic N-acetylation, with clinically important differences between fast and slow acetylator phenotypes
D) Glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes, with minimal cytochrome P450 involvement
E) Elimination entirely as unchanged drug by glomerular filtration, with no significant hepatic metabolism
ANSWER: D
Rationale:
The SGLT-2 inhibitor class is metabolized primarily by glucuronidation through UDP-glucuronosyltransferase (UGT) enzymes, with minimal cytochrome P450 (CYP450) involvement; for example, canagliflozin is glucuronidated by UGT1A9 and UGT2B4, and dapagliflozin by UGT1A9.
Option A: Option A is incorrect because the class is not extensively CYP3A4-metabolized and is not highly susceptible to CYP3A4 interactions.
Option B: Option B is incorrect because the agents are not inactivated by plasma esterase hydrolysis within minutes; they have half-lives of roughly 10 to 13 hours and undergo glucuronidation.
Option C: Option C is incorrect because N-acetylation with acetylator-phenotype variability is not the metabolic route for this class.
Option E: Option E is incorrect because the agents undergo substantial glucuronidation rather than being eliminated entirely as unchanged drug by filtration.
7. Which statement correctly pairs an SGLT-2 inhibitor with a distinguishing administration or historical fact?
A) Ertugliflozin was the first SGLT-2 inhibitor approved in the United States and is the most widely studied agent of the class
B) Canagliflozin was the first SGLT-2 inhibitor approved in the United States and is taken before the first meal of the day
C) Dapagliflozin must be taken with a high-fat meal to achieve adequate absorption
D) Empagliflozin was the first SGLT-2 inhibitor approved in the United States and must be dosed twice daily
E) Canagliflozin is administered exclusively at bedtime to minimize daytime glycosuria
ANSWER: B
Rationale:
Canagliflozin was the first SGLT-2 inhibitor approved in the United States (March 2013) for glycemic control in type 2 diabetes mellitus, and it is taken before the first meal of the day.
Option A: Option A is incorrect because ertugliflozin was the most recently approved and least studied agent of the four, not the first approved.
Option C: Option C is incorrect because dapagliflozin is taken without regard to meals and does not require a high-fat meal for absorption.
Option D: Option D is incorrect because empagliflozin was not the first agent approved and is dosed once daily, not twice daily.
Option E: Option E is incorrect because canagliflozin is taken before the first meal of the day, not exclusively at bedtime.
8. For a given SGLT-2 inhibitor, how does the estimated glomerular filtration rate (eGFR) threshold for use relate to the indication being treated?
A) The eGFR floor is generally higher for the glycemic indication (around 45 mL/min/1.73 m2) than for cardiovascular or renal indications, where dapagliflozin and empagliflozin may be used down to roughly 20 to 25 mL/min/1.73 m2
B) The eGFR floor is identical across all indications for a given agent, so the indication has no bearing on the threshold
C) The eGFR floor is lower for the glycemic indication than for cardiorenal indications, because glucose lowering requires less renal function
D) The eGFR floor is fixed at 60 mL/min/1.73 m2 for all indications and all agents
E) The eGFR floor applies only to the glycemic indication; cardiovascular and renal indications have no eGFR threshold at all
ANSWER: A
Rationale:
For a given SGLT-2 inhibitor, the eGFR threshold is indication-dependent. The glycemic indication generally requires a higher eGFR (around 45 mL/min/1.73 m2), reflecting the fact that glycosuric efficacy diminishes as filtration falls, whereas the cardiovascular and renal indications permit lower floors, with dapagliflozin and empagliflozin usable for heart failure or chronic kidney disease down to roughly 20 to 25 mL/min/1.73 m2.
Option B: Option B is incorrect because the floor is not identical across indications; it differs by indication for the same agent.
Option C: Option C is incorrect because it inverts the relationship: the glycemic floor is higher, not lower, than the cardiorenal floor.
Option D: Option D is incorrect because there is no single fixed 60 mL/min/1.73 m2 floor across all indications and agents.
Option E: Option E is incorrect because the cardiovascular and renal indications do have defined eGFR floors; they are simply lower than the glycemic floor.
9. Which statement correctly describes the type 2 diabetes mellitus (T2DM) requirement for the major approved indications of dapagliflozin and empagliflozin?
A) Both agents require a T2DM diagnosis for every approved indication, including heart failure and chronic kidney disease
B) Both agents are approved only for glycemic control and have no approved cardiovascular or renal indications
C) Both agents are approved for heart failure and for chronic kidney disease regardless of T2DM status, in addition to their glycemic indication in T2DM
D) Both agents are approved for heart failure and chronic kidney disease only in patients who do NOT have T2DM
E) Only empagliflozin has non-glycemic indications; dapagliflozin is restricted to glycemic control in T2DM
ANSWER: C
Rationale:
Dapagliflozin and empagliflozin are approved for heart failure (across the ejection fraction spectrum) and for chronic kidney disease (CKD) regardless of T2DM status, in addition to their glycemic indication in T2DM. A patient with heart failure or CKD but without diabetes can therefore receive either agent for the cardiorenal indication.
Option A: Option A is incorrect because the heart failure and CKD indications explicitly do not require a T2DM diagnosis.
Option B: Option B is incorrect because both agents have well-established cardiovascular (heart failure) and renal indications beyond glycemic control.
Option D: Option D is incorrect because the cardiorenal approvals apply regardless of diabetes status, not only to patients without T2DM.
Option E: Option E is incorrect because both dapagliflozin and empagliflozin carry non-glycemic indications; dapagliflozin is not restricted to glycemic control.
10. A clinician wants an SGLT-2 inhibitor specifically to obtain a proven cardiovascular or renal outcome benefit. Why is ertugliflozin a poor choice for that goal?
A) Ertugliflozin is contraindicated in all patients with any cardiovascular disease because it worsens heart failure outcomes
B) Ertugliflozin cannot be used for glycemic control and is approved only as adjunctive weight-loss therapy
C) Ertugliflozin has the highest selectivity of the class and therefore produces no glycosuria, eliminating any metabolic benefit
D) Ertugliflozin has no approved non-glycemic (cardiovascular or renal) indications, and its cardiovascular outcome data demonstrated cardiovascular safety (non-inferiority) without proving superiority for the primary major adverse cardiovascular event endpoint
E) Ertugliflozin is the only agent that requires twice-daily dosing, which is the reason it lacks outcome benefit
ANSWER: D
Rationale:
Ertugliflozin does not have approved non-glycemic indications beyond type 2 diabetes mellitus, and its cardiovascular outcome data established cardiovascular safety by meeting non-inferiority but did not demonstrate superiority over placebo for the primary major adverse cardiovascular event (MACE) endpoint. For a clinician seeking a proven cardiorenal outcome benefit, an agent with positive outcome indications (such as dapagliflozin or empagliflozin) is the appropriate choice.
Option A: Option A is incorrect because ertugliflozin is not contraindicated in all cardiovascular disease and was not shown to worsen heart failure outcomes; it simply lacks a proven benefit indication.
Option B: Option B is incorrect because ertugliflozin is approved for glycemic control in T2DM and is not a weight-loss-only agent.
Option C: Option C is incorrect because ertugliflozin does produce glycosuria; selectivity does not abolish its glucose-lowering effect.
Option E: Option E is incorrect because ertugliflozin is dosed once daily, and dosing frequency is not the reason it lacks an outcome-benefit indication.
11. Which definition best characterizes euglycemic diabetic ketoacidosis (DKA) associated with SGLT-2 inhibitor therapy?
A) Ketoacidosis accompanied by plasma glucose above 600 mg per deciliter and a hyperosmolar state
B) A hyperglycemic state without ketosis, defined by glucose above 250 mg per deciliter and normal serum ketones
C) Lactic acidosis with normal ketone levels occurring in the setting of normal glucose
D) An anion-gap acidosis caused purely by renal bicarbonate wasting without ketone production
E) Ketoacidosis that develops without markedly elevated plasma glucose, typically with glucose below approximately 252 mg per deciliter (14 mmol per liter)
ANSWER: E
Rationale:
Euglycemic DKA is ketoacidosis that develops without markedly elevated plasma glucose, typically with glucose below approximately 14 millimoles per liter (252 mg per deciliter). The glycosuric effect of SGLT-2 inhibition prevents glucose accumulation while glucagon excess drives hepatic ketogenesis, so the diagnostic danger is that the near-normal glucose can mask the acidosis.
Option A: Option A is incorrect because euglycemic DKA specifically lacks markedly elevated glucose; glucose above 600 mg per deciliter with hyperosmolarity describes hyperosmolar hyperglycemic state.
Option B: Option B is incorrect because euglycemic DKA is a ketoacidosis (ketones are elevated and acidosis is present), not a hyperglycemic state without ketosis.
Option C: Option C is incorrect because the entity is a ketoacidosis driven by ketone production, not a lactic acidosis with normal ketones.
Option D: Option D is incorrect because the acidosis is driven by ketone (beta-hydroxybutyrate) production, not purely by renal bicarbonate wasting without ketones.
12. Which adverse effect occurs most frequently with SGLT-2 inhibitor therapy?
A) Fournier gangrene, a common complication seen in roughly 1 in 10 treated patients
B) Genital mycotic infection (vulvovaginal candidiasis in women, balanitis in uncircumcised men), the most common adverse effect, occurring in roughly 6 to 14% of women and 3 to 5% of men
C) Severe hypoglycemia, occurring in the majority of treated patients because of the insulin-independent mechanism
D) Acute pancreatitis, the most common adverse effect, occurring in approximately 20% of treated patients
E) Euglycemic diabetic ketoacidosis, which is the single most frequent adverse effect of the class
ANSWER: B
Rationale:
Genital mycotic infections are the most common adverse effect of SGLT-2 inhibitors, occurring in approximately 6 to 14% of women and 3 to 5% of men, because glucosuria creates a favorable environment for Candida growth in the genital area; most cases are mild to moderate and respond to standard antifungal treatment.
Option A: Option A is incorrect because Fournier gangrene is a rare (roughly 1 per 10,000 patient-years), not common, complication.
Option C: Option C is incorrect because the insulin-independent mechanism makes severe hypoglycemia uncommon with SGLT-2 inhibitor monotherapy, not a majority occurrence.
Option D: Option D is incorrect because acute pancreatitis is not the most common adverse effect and does not occur in anything approaching 20% of patients.
Option E: Option E is incorrect because euglycemic DKA, though the most serious metabolic complication, is uncommon and is not the most frequent adverse effect; genital mycotic infection is.
13. What is Fournier gangrene, and what is the appropriate response when it is suspected in a patient taking an SGLT-2 inhibitor?
A) Necrotizing fasciitis of the perineum and genitalia; the SGLT-2 inhibitor should be discontinued and immediate surgical consultation obtained because mortality is high without early debridement
B) A benign superficial fungal rash of the groin that resolves with topical antifungal cream while the drug is continued
C) A self-limited viral exanthem requiring only supportive care and no change to therapy
D) A chronic indolent cellulitis that is managed with several weeks of oral antibiotics in the outpatient setting
E) An allergic contact dermatitis caused by the drug that resolves spontaneously once the dose is reduced
ANSWER: A
Rationale:
Fournier gangrene is a rare but life-threatening necrotizing fasciitis of the perineum and genitalia associated with SGLT-2 inhibitor use. When suspected, the SGLT-2 inhibitor should be discontinued and immediate surgical consultation obtained, because mortality is high without early surgical debridement.
Option B: Option B is incorrect because Fournier gangrene is a life-threatening necrotizing infection, not a benign superficial fungal rash, and the drug should be stopped rather than continued.
Option C: Option C is incorrect because it is a polymicrobial necrotizing fasciitis, not a self-limited viral exanthem.
Option D: Option D is incorrect because it is fulminant and requires urgent surgical management, not weeks of outpatient oral antibiotics.
Option E: Option E is incorrect because it is not an allergic contact dermatitis and does not resolve with dose reduction; it is a surgical emergency.
14. How far in advance of a planned major surgery should an SGLT-2 inhibitor be discontinued to reduce the risk of perioperative euglycemic diabetic ketoacidosis?
A) On the morning of surgery only
B) 2 weeks before surgery
C) 3 to 4 days before surgery
D) No discontinuation is necessary at any point
E) 12 hours before surgery
ANSWER: C
Rationale:
Because SGLT-2 inhibitors predispose to euglycemic diabetic ketoacidosis during the relative insulin deficiency of surgery and fasting, the perioperative protocol calls for discontinuing them 3 to 4 days before planned major surgery, with resumption only after the patient is eating and drinking normally and ketones are negative.
Option A: Option A is incorrect because holding only on the morning of surgery does not allow sufficient washout given the drug's pharmacodynamic persistence.
Option B: Option B is incorrect because a 2-week hold is longer than required and would unnecessarily withhold therapy; 3 to 4 days is the established interval.
Option D: Option D is incorrect because discontinuation is necessary to reduce perioperative euglycemic ketoacidosis risk.
Option E: Option E is incorrect because a 12-hour hold is insufficient; the recommended interval is 3 to 4 days.
15. A patient with peripheral arterial disease and prior foot ulceration needs an SGLT-2 inhibitor. Which agent-specific safety consideration is most relevant to agent selection?
A) The amputation and fracture signals are uniform class effects, so agent choice makes no difference for this patient
B) Empagliflozin carries the strongest amputation signal of the class and should be specifically avoided here
C) Dapagliflozin carries a black-box amputation warning that makes it the highest-risk agent for this patient
D) The increased amputation and bone-fracture signals are considered largely canagliflozin-specific (identified in the CANVAS program) and have not been consistently replicated across the class, so caution with canagliflozin in particular is warranted in patients with peripheral arterial disease or prior amputation
E) None of the SGLT-2 inhibitors has ever been associated with an amputation signal, so this concern is irrelevant
ANSWER: D
Rationale:
The increased lower-extremity amputation signal (and the bone-fracture signal) was identified with canagliflozin in the CANVAS program and is considered largely canagliflozin-specific; it has not been consistently replicated across the class or even across all canagliflozin trials. Caution with canagliflozin in particular is therefore warranted in patients with peripheral arterial disease, prior amputation, active foot ulcers, or neuropathy, and selecting a different agent is reasonable.
Option A: Option A is incorrect because the signal is not a uniform class effect; it is concentrated with canagliflozin, so agent choice does matter.
Option B: Option B is incorrect because empagliflozin does not carry the strongest amputation signal; the signal is associated with canagliflozin.
Option C: Option C is incorrect because the amputation signal is associated with canagliflozin, not dapagliflozin.
Option E: Option E is incorrect because an amputation signal was in fact observed with canagliflozin, so the concern is not irrelevant.
16. A patient on insulin is starting an SGLT-2 inhibitor. Which combination and initiation principle is correct?
A) A second SGLT-2 inhibitor should be added simultaneously to maximize glycosuria, and insulin should be increased at initiation
B) The insulin should be stopped entirely at the moment the SGLT-2 inhibitor is started, regardless of the patient's regimen
C) SGLT-2 inhibitors cannot be combined with insulin under any circumstances because of an unacceptable interaction
D) The SGLT-2 inhibitor dose should be tripled when given with insulin to overcome insulin-related resistance
E) Two SGLT-2 inhibitors should never be combined with each other, and when an SGLT-2 inhibitor is added to insulin the insulin dose is typically reduced by about 20% at initiation to limit hypoglycemia risk
ANSWER: E
Rationale:
SGLT-2 inhibitors should never be combined with one another. They can be combined with insulin, and when added to insulin the insulin dose is typically reduced by approximately 20% at initiation to limit the risk of hypoglycemia from the added glucose-lowering effect.
Option A: Option A is incorrect because two SGLT-2 inhibitors should not be combined, and insulin is reduced rather than increased at initiation.
Option B: Option B is incorrect because insulin is not stopped entirely; it is dose-reduced by roughly 20%, with the regimen individualized.
Option C: Option C is incorrect because SGLT-2 inhibitors can be safely combined with insulin, with appropriate dose adjustment.
Option D: Option D is incorrect because the SGLT-2 inhibitor dose is not tripled when given with insulin; the relevant adjustment is a reduction in the insulin dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.